Tilray Brands, Inc. (TLRY)
NASDAQ: TLRY · Real-Time Price · USD
1.200
+0.020 (1.69%)
Jan 17, 2025, 4:00 PM EST - Market closed
Tilray Brands Revenue
Tilray Brands had revenue of $210.95M in the quarter ending November 30, 2024, with 8.87% growth. This brings the company's revenue in the last twelve months to $829.22M, up 18.38% year-over-year. In the fiscal year ending May 31, 2024, Tilray Brands had annual revenue of $788.94M with 25.80% growth.
Revenue (ttm)
$829.22M
Revenue Growth
+18.38%
P/S Ratio
1.17
Revenue / Employee
$312,912
Employees
2,650
Market Cap
1.13B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
May 31, 2024 | 788.94M | 161.82M | 25.80% |
May 31, 2023 | 627.12M | -1.25M | -0.20% |
May 31, 2022 | 628.37M | 115.29M | 22.47% |
May 31, 2021 | 513.09M | 107.76M | 26.59% |
May 31, 2020 | 405.33M | 226.02M | 126.06% |
May 31, 2019 | Pro | Pro | Pro |
May 31, 2018 | Pro | Pro | Pro |
May 31, 2017 | Pro | Pro | Pro |
May 31, 2016 | Pro | Pro | Pro |
May 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
TLRY News
- 3 days ago - Canadian Marijuana Stocks To Watch To Close Out The Week - MarijuanaStocks
- 6 days ago - Tilray: Back To Square One (Rating Downgrade) - Seeking Alpha
- 10 days ago - Tilray Brands, Inc. (TLRY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Cannabis/Beer Company Tilray Outlines Plan To Reduce Its Beverage Portfolio, Reports Mixed Q2 Earnings - Benzinga
- 10 days ago - Tilray's stock slumps as cannabis and beer maker plans to cut its drinks lineup - Market Watch
- 10 days ago - Tilray Brands Reports Q2 2025 Financial Results - GlobeNewsWire
- 12 days ago - Tilray: FQ2 Results Unlikely To Impress Below The Top Line - Seeking Alpha
- 13 days ago - Top Canadian Cannabis Stocks to Watch for Breakout Opportunities in 2025 - MarijuanaStocks